Alumis Upgraded to Buy Following Positive Phase 3 Psoriasis Drug Data

Alumis Inc. (ALMS) received a stock rating upgrade to 'Buy' following the release of strong Phase 3 clinical trial data for its psoriasis treatment, envudeucitinib. The drug demonstrated a 74% efficacy rate on the PASI 75 scale, placing it in direct competition with Johnson & Johnson’s recently approved Icotyde. Analysts highlighted the drug's potential to capture significant market share in the oral psoriasis medication space due to its competitive clinical profile. The company has outlined a regulatory roadmap, targeting a New Drug Application (NDA) submission in the second half of 2026. While the long-term timeline for commercialization remains a factor, the clinical success significantly de-risks the company's primary asset. Market participants are also looking forward to additional data readouts expected in 2026 for other potential indications of the drug.

Sources:seekingalpha.cominvestors.alumis.comglobenewswire.comstocktitan.netmarketscreener.commarketchameleon.comainvest.comintellectia.aitipranks.comsimplywall.stng.investing.comfinviz.combenzinga.commarketbeat.comdirectorstalkinterviews.comsahmcapital.comStock Titan